Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heparin polyaldehyde
- Development stage
- Preclinical
- Lead developer
- King's College London
- Modality
- Small Molecules
01
Overview
Heparin polyaldehyde (also referred to as heparin-polyaldehyde or oxidized heparin) is a modified form of heparin prepared by the periodate oxidation of heparin. This chemical modification introduces reactive aldehyde groups onto the heparin backbone while preserving its core anticoagulant properties. It has been investigated primarily as a bioactive component in multilayer nanocoatings (often layered with cationic polymers like glycol chitosan) designed to encapsulate pancreatic islets. This protective nanocoating aims to prevent the instant blood-mediated inflammatory response (IBMIR) and improve graft survival following islet transplantation in patients with type 1 diabetes.
- Other names
- heparin-poly-aldehydeheparin-polyaldehydeoxidized heparin
02
Targets
ATIII (Antithrombin III)
Beyond the preview
Go deeper on heparin polyaldehyde.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heparin polyaldehyde.